Dafna Capital Management
Dafna Capital Management is an investment advisor that specializes in managing client portfolios of biotechnology companies.
Business Model:
Revenue: $13.1M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Dafna Capital Management Information
Geographic Data
Address: 10990 Wilshire Boulevard Suite 1400
City: Los Angeles
State: CA
Zip: 90024
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
3,487,756Website Global Rank
1,364Website Monthly Traffic
Twitter Followers
Description
DAFNA Capital Management, LLC, a Los Angeles based SEC registered investment advisor, specializes in managing long/short portfolios of predominantly publicly traded biotechnology and medical device companies. Founded in 1999, for over 17 years we have merged unparalleled expertise, intellectual curiosity, and investment rigor to fund the future of medicine and prudently manage the wealth entrusted with us by our investors
Contact Phone:
+13109543200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 6/2016 | arGEN-X | Post-IPO Equity | 34.1M |
| 9/2010 | Cascadian Therapeutics | Post-IPO Equity | 0 |
| 8/2010 | Raptor Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 7/2010 | Soligenix | Venture Round | 0 |
| 6/2021 | KAHR medical | Venture Round | 0 |
| 11/2015 | ObsEva | Series B | 60M |
| 10/2008 | Micromet | Post-IPO Equity | 0 |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 6/2021 | KAHR medical | Venture Round | 0 |
| 2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
| 10/2017 | ObsEva | Post-IPO Equity | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2016 | arGEN-X | Post-IPO Equity | 0 |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 9/2010 | Cascadian Therapeutics | Post-IPO Equity | 0 |
| 8/2010 | Raptor Pharmaceuticals | Post-IPO Equity | 0 |
| 7/2010 | Soligenix | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
